Susi Roger E. 4
4 · IRADIMED CORP · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
IRADIMED (IRMD) 10% Owner Roger E. Susi Sells Shares
What Happened
Roger E. Susi, a 10% owner of IRADIMED CORP (IRMD), sold a total of 7,500 shares in open-market transactions on March 16–17, 2026, for aggregate proceeds of approximately $762,971. The sales were: 3,009 shares at a weighted-average $101.18 ($304,451), 1,991 shares at $101.68 ($202,445), and 2,500 shares at $102.43 ($256,075). These were sales (not purchases), which are often routine liquidity events rather than a bullish signal.
Key Details
- Transaction dates: Mar 16, 2026 (two blocks) and Mar 17, 2026 (one block). All reported on Form 4 filed Mar 18, 2026 (timely).
- Prices reported: $101.18, $101.68, $102.43 (each is a weighted-average price; underlying trades were executed across the ranges noted in the footnotes).
- Total shares sold: 7,500; total proceeds: ~$762,971.
- Shares owned after transaction: Not disclosed in the provided filing details.
- Notable footnotes:
- F1: Sales were made pursuant to a Rule 10b5‑1 trading plan adopted Nov 5, 2025.
- F2–F4: Each reported price is a weighted average of multiple trades (ranges provided in the filing).
- F5: The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
- Filing timeliness: Reported within the typical two-business-day window (no late filing indicated).
Context
A 10b5‑1 plan lets insiders sell pre-scheduled amounts to avoid questions about trading on material nonpublic information; its presence means these sales were executed under a previously established plan. As these are sales by a 10% owner (a significant insider), they are notable for share movement and liquidity but do not, by themselves, indicate the insider’s view of the company’s prospects.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-16$101.18/sh−3,009$304,451→ 2,244,491 total(indirect: By Trust) - Sale
Common Stock
[F1][F3]2026-03-16$101.68/sh−1,991$202,445→ 2,242,500 total(indirect: By Trust) - Sale
Common Stock
[F1][F4]2026-03-17$102.43/sh−2,500$256,075→ 2,240,000 total(indirect: By Trust)
- 162,950(indirect: By Trust)
Common Stock
- 2,062,500(indirect: By Trust)
Common Stock
[F5]
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $100.37 to $101.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $101.38 to $101.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $102.06 to $102.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.